leadf
logo-loader
viewSareum Holdings PLC

Sareum says progress has been good across a range of programmes

Company expects to hear this month whether it will receive grant funding for preliminary studies of a coronavirus (COVID-19) anti-inflammatory.

Sareum Holdings PLC -

Sareum Holdings PLC (LON:SAR), the small molecule therapeutics specialist, has said it expects to hear this month whether it will receive grant funding for preliminary studies of a coronavirus (COVID-19) anti-inflammatory.

An application has been submitted to the UK Research and Innovation (UKRI) to fund preliminary laboratory studies into whether TYK2/JAK1 inhibitors can alleviate the  "cytokine storm" and other potentially fatal respiratory symptoms of COVID-19.

If the grant application is successful, initial studies will begin shortly thereafter said Sareum in its statement of results for the year to end June.

Sareum said it had also made a breakthrough with autoimmune treatment SDC-1801 through a new formulation that will enable a higher, therapeutic dose.

Further toxicology studies need to be carried out before human trials start but it said tolerability in rodents had been excellent and it expects to apply to start a human trial early next year.

Elsewhere, Sareum noted that it has also completed formulation work for oral dosing of cancer immunotherapy candidate SDC-1802 during the full-year.

On its licensed programmes, Sareum highlighted recent reports that Sierra Oncology has completed Phase 1/2 trials of SRA737 as a monotherapy and in combination with low dose gemcitabine.

Sareum also signed a deal for its FLT3+Aurora inhibitor programme targeting blood cancers with a China-based speciality pharma company during the period and success-dependent milestone payment is possible by January 2021 under this agreement.  

In the statement, Dr Tim Mitchell, the group's chief executive, said: "Sareum has continued to make good progress with the preclinical development of our proprietary dual TYK2/JAK1 inhibitor programmes.

"Most recently, we have overcome an important formulation challenge with SDC-1801, which will now be advanced into the toxicology studies needed to complete our preparations for clinical trials."

He added: "Regarding SRA737, we continue to monitor Sierra Oncology's activities as it explores options to fund the future development of this novel compound. We were pleased to note that as of 25 September 2020, the website www.clinicaltrials.gov is reporting that the Phase 1/2 trials of SRA737 as a monotherapy and in combination with low dose gemcitabine in solid cancers are complete.

“We look forward to the results of these completed trials being disclosed. We will provide further updates on this and other programmes when appropriate."

Sareum's losses for the year to end June were  £0.99m (2019: loss of £1.45mln) with cash in the bank of £1.80mln at the end of the period.

Quick facts: Sareum Holdings PLC

Price: 2.184 GBX

AIM:SAR
Market: AIM
Market Cap: £71.37 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Sareum Holdings PLC named herein, including the promotion by the Company of Sareum Holdings PLC in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Sareum Holdings focused on striking a deal for its immunotherapies

Sareum Holdings PLC's (LON:SAR) Tim Mitchell tells Proactive London's Andrew Scott they're advancing initial discussions with potential licensees for its pre-clinical tyrosine kinase 2 (TYK2) / Janus kinase 1 (JAK1) inhibitor immunotherapies for autoimmune diseases and cancer. He says they're...

on 12/8/20

2 min read